Sanofi (NASDAQ:SNY) Stock Position Cut by Van ECK Associates Corp

Van ECK Associates Corp lessened its stake in Sanofi (NASDAQ:SNY) by 1.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 401,374 shares of the company’s stock after selling 7,633 shares during the quarter. Van ECK Associates Corp’s holdings in Sanofi were worth $19,960,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Altrius Capital Management Inc lifted its holdings in Sanofi by 1.7% in the 4th quarter. Altrius Capital Management Inc now owns 135,311 shares of the company’s stock valued at $6,729,000 after acquiring an additional 2,318 shares during the last quarter. Transcend Capital Advisors LLC lifted its holdings in Sanofi by 5.7% in the 4th quarter. Transcend Capital Advisors LLC now owns 5,730 shares of the company’s stock valued at $285,000 after acquiring an additional 307 shares during the last quarter. Unique Wealth Strategies LLC acquired a new stake in Sanofi in the 4th quarter valued at about $577,000. Atria Wealth Solutions Inc. lifted its holdings in Sanofi by 7.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 16,370 shares of the company’s stock valued at $814,000 after acquiring an additional 1,205 shares during the last quarter. Finally, Wynn Capital LLC acquired a new stake in Sanofi in the 4th quarter valued at about $251,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

SNY stock opened at $49.23 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a one year low of $42.63 and a one year high of $55.93. The firm has a market capitalization of $124.53 billion, a PE ratio of 24.74, a P/E/G ratio of 1.37 and a beta of 0.61. The firm has a 50-day moving average of $47.82 and a two-hundred day moving average of $48.25.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. On average, analysts forecast that Sanofi will post 4.11 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a $1.478 dividend. This represents a dividend yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is 69.35%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SNY shares. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, Morgan Stanley initiated coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.